Prevention and Management of NSAID-Induced Gastropathy

REFERENCES

• Roth S H. NSAID Gastropathy. Arch Intern Med 1996; 156: 1623–8
   PubMedGoogle Scholar
• Winzeler S, Rosenstein B D. Non-steroidal antiinflammatory drugs: A review. AAOHN J 1998; 46: 253–9
   PubMedGoogle Scholar
• Lanza F L. A guideline for the treatment and prevention of NSAID-induced ulcers. Am J Gastroenterol 1998; 93: 2037–46
   PubMed Web of Science ®Google Scholar
• Singh G, Rameyu D R, Morfeld D, Shi H, Hatoum H T, Fries J F. Gastrointestinal tract complications of nonsteroidal antiinflammatory drug treatment in rheumatoid arthritis: A prospective observational cohort study. Arch Intern Med 1996; 156: 1530–6
   PubMed Web of Science ®Google Scholar
• McCarthy D. Nonsteroidal antiinflammatory drug-related gastrointestinal toxicity: Definitions and epidemiology. Am J Med 1998; 105: 3S–9S
   PubMedGoogle Scholar
• Tannenbaum H, Davis P, Russell A S, et al. An evidence-based approach to prescribing NSAIDs in musculoskeletal disease: A Canadian consensus. Can Med Assoc J 1996; 155: 77–88
   Google Scholar
• Polisson R. Nonsteroidal antiinflammatory drugs: Practical and theoretical considerations in their selection. Am J Med 1996; 100: 31S–36S
   PubMed Web of Science ®Google Scholar
• Singh G. Recent considerations in nonsteroidal antiinflammatory drug gastropathy. Am J Med 1998; 105: 31S–38S
   PubMedGoogle Scholar
• Peskar B M, Maricic N. Role of prostaglandins in gastroprotection. Digestive Dis Sci 1998; 43: 23S–29S
   PubMed Web of Science ®Google Scholar
• Rothstein R. Safety profiles of leading nonsteroidal antiinflammatory drugs. Am J Med 1998; 105: 39S–43S
   PubMedGoogle Scholar
• Needleman P, Isakson P C. The discovery and function of COX-2. J Rheumatol 1997; 24: 6–7
   PubMedGoogle Scholar
• Lipsky P E. Progress toward a new class of therapeutics: Selective COX-2 inhibition. J Rheumatol 1997; 24: 1
   PubMedGoogle Scholar
• Crofford L J. COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol 1997; 24: 15–9
   Web of Science ®Google Scholar
• Wolfe M M. Future trends in the development of safer nonsteroidal antiinflammatory drugs. Am J Med 1998; 105: 44S–52S
   Web of Science ®Google Scholar
• Soll A. Pathogenesis of nonsteroidal antiinflammatory drug-related upper gastrointestinal toxicity. Am J Med 1998; 105: 10S–16S
   Google Scholar
• McCarthy D M. Mechanisms of mucosal injury and healing: the role of non-steroidal antiinflammatory drugs. Scand J Gastroenterol 1995; 30: 24–9
   Web of Science ®Google Scholar
• Wolfe M M. Gastrointestinal toxicity of the nonsteroidal antiinflammatory drugs. N Eng J med 1999; 340: 1888–99
   PubMed Web of Science ®Google Scholar
• Day R O, Graham G G, Williams K M, Champion G D, Jager J. Clinical Pharmacology of non-steroidal antiinflammatory drugs. Pharmac. Ther 1987; 33: 383–453
   Google Scholar
• Cryer B. Nonsteroidal antiinflammatory drugs and gastrointestinal disease. Gastointestinal and Liver Diseases: Pathophysiology, Diagnosis, Management, M Feldman, B F Scharschmidt, M H Seusenger. W.B. Saunders, Co., Philadelphia, PA 1998; 1: 343–57
   Google Scholar
• Reuben S S, Steinberg R. Gastric perforation associated with the use of celecoxib. Anesthesiology 1999; 91: 1548–9
   PubMedGoogle Scholar
• Levi S, Goodlad R A, Lee C Y. Inhibitory effect of nonsteroidal antiinflammatory drugs on mucosal cell proliferation associated with gastric ulcer healing. Lancet 1990; 336: 840–3
   PubMed Web of Science ®Google Scholar
• Barkin J. The relation between Helicobacter pylori and nonsteroidal antiinflammatory drugs. Am J Med 1998; 105: 22S–27S
   Google Scholar
• Scheiman J, Isenberg J. Agents used in the prevention and treatment of non-steroidal antiinflammatory drug-associated symptoms and ulcers. Am J Med 1998; 105: 32S–38S
   Google Scholar
• Hawkey C J, Karrasch J A, Szcezepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998; 338: 727–34
   PubMed Web of Science ®Google Scholar
• Silverstein F E. Improving the gastrointestinal safety of NSAIDs: The development of misoprostol—From hypothesis to clinical practice. Digestive Dis Sci 1998; 43: 447–58
   PubMedGoogle Scholar
• Lane N E. Pain management in osteoarthritis: The role of COX-2 inhibitors. J Rheumatol 1997; 24: 20–4
   PubMedGoogle Scholar
• Lipsky P E, Isakson P C. Outcome of specific COX-2 inhibition in rheumatoid arthritis. J Rheumatol 1997; 24: 9–14
   PubMed Web of Science ®Google Scholar
• Celebrex (celecoxib capsules) product information. Chicago. G.D. Searle, December, IL 1998
   Google Scholar
• Vioxx (rofecoxib tablets and oral suspension) product information. West Point. Merck & Co., Inc., September, PA 1999
   Google Scholar
• Kaplan-Machlis B, Klostermeyer B S. The cyclooxygnease-2 inhibitors: Safety and effectiveness. Ann Pharmacother 1999; 33: 979–88
   PubMed Web of Science ®Google Scholar
• Langman M J, Jensen D M, Watson D J, et al. Adverse upper gastointestinal effects of refecoxib compared with NSAIDs. J Am Med Assoc 1999; 282: 1929–33
   PubMed Web of Science ®Google Scholar